S
SELLAS Life Sciences Group Inc.
Biotechnology: Pharmaceutical Preparations company
Key Metrics of SELLAS Life Sciences Group Inc.
Revenue$0▼ 100.0% YoYFY 2023
Operating income−$37.9M▲ 9.7% YoY
Net profit−$37.3M▲ 9.6% YoY
Shareholders' equity−$8.0M
Market cap$2.5BSLS · $12.14
Competitors10identified
About SELLAS Life Sciences Group Inc.
Sectors
Company details
- Listed
- Nasdaq: SLS
Operational Areas of SELLAS Life Sciences Group Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameSELLAS Life Sciences Group Inc.
TickerSLS
ExchangeNasdaq
CountryUnited States
SEC CIK0001390478
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
SLS · Nasdaq · SEC CIK 0001390478
Last price · 23 Oct 2026
$12.14
+1.34%
Market cap$2.5B
P/E—On FY 2023 diluted EPS
Volume5,656,087
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
SLS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of SELLAS Life Sciences Group Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Similar companies
H
Hester Biosciences LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medicamen Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Concord Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
China SXT Pharmaceuticals Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Novartis AGPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Neurocrine BiosciencesPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
BioMarin PharmaceuticalPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Bio-Rad LaboratoriesPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.